Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07271186

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.

The aim of the study is to see how safe and effective the study drugs are.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diabetic Kidney Disease (DKD) Chronic Disease Diabetes Complications Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetic Nephropathies Disease Attributes Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Kidney Diseases Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Apogee Clinical Research, LLC, Huntsville, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
  • Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
  • eGFR 30 to 90 mL/min/1.73 m^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
  • Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening

Key Exclusion Criteria:

  • Known medical history or clinical evidence indicative of non-diabetic renal disease
  • Renal disease that required treatment with systemic immunosuppressive therapy, or a history of dialysis or renal transplant
  • Medically unstable as assessed by the investigator
  • Hospitalization (ie, >24 hours) within 30 days of the screening visit

NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Treatment and study plan

ALN-ANG3

Drug

Administered per the protocol

Evinacumab

Drug

Administered per the protocol

Other names: Evkeeza®, R1500

ALN-ANG3 placebo

Drug

Administered per the protocol

Evinacumab placebo

Drug

Administered per the protocol

Primary outcomes

  1. Percent change in Urine Albumin to Creatinine Ratio (UACR)

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline to Week 24

  2. Change in total cholesterol

    Time frame: Baseline to Week 24

  3. Change in Low-Density Lipoprotein-Cholesterol (LDL-C)

    Time frame: Baseline to Week 24

  4. Change in High-Density Lipoprotein-Cholesterol (HDL-C)

    Time frame: Baseline to Week 24

  5. Change in non-High-Density Lipoprotein-Cholesterol (non-HDL-C)

    Time frame: Baseline to Week 24

  6. Change in triglycerides

    Time frame: Baseline to Week 24

  7. Change in Apolipoprotein B (ApoB)

    Time frame: Baseline to Week 24

  8. Concentration of combined ALN-ANG3 and metabolite(s) and evinacumab

    Time frame: Up to Week 24

  9. Change in concentration of Angiopoietin-Like Protein-3 (ANGPTL-3)

    Time frame: Baseline to Week 24

  10. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 48

  11. Severity of TEAEs

    Time frame: Up to Week 48

  12. Incidence of ADAs to ALN-ANG3

    Time frame: Through Week 24

  13. Magnitude of ADAs to ALN-ANG3

    Time frame: Through Week 24

  14. Incidence of ADAs to evinacumab

    Time frame: Through Week 24

  15. Magnitude of ADAs to evinacumab

    Time frame: Through Week 24

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Administrator

CONTACT

[email protected]

844-734-6643

Sponsors and collaborators

Lead sponsor

Regeneron Pharmaceuticals

Industry

Registry information

Official study title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease

Acronym: ANCHOR-POC

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Dec 9, 2025
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.